enVVeno Medical Corporation - רווח נקי למניה אחת בשנים עשר החודשים האחרונים NVNO

The development of the enVVeno Medical (NVNO) bioprosthetic ecosystem depends entirely on the FDA decision. The TTM annual net income per share trend visualizes current stagnation, where the value 40.20 serves as the target level. Fundamentally, enVVeno Medical (NVNO) relies on partnerships with surgical centers to promote VenoValve, while simultaneously minimizing risks by creating unique solutions for chronic venous insufficiency.
enVVeno Medical Corporation - פילוחים אנליטיים ומדדי מפתח (NVNO)

This indicator measures the annual growth rate of earnings per share over the last 12 months, allowing for an assessment of capital generation efficiency relative to previous periods. By analyzing the annual percentage change in EPS TTM, an investor can observe the financial performance of enVVeno Medical (NVNO), which is currently secondary for the company due to its focus on completing FDA clinical trials and preparing for the commercialization of bioprostheses.